IDEXX Laboratories vs Zoetis Which Is More Lucrative?

IDEXX Laboratories and Zoetis are two leading companies in the animal health industry, both specializing in developing and manufacturing products for the veterinary market. While IDEXX focuses primarily on diagnostic and software solutions for veterinarians, Zoetis offers a wide range of animal health products, including vaccines and medicines. Both companies have experienced strong growth in recent years, attracting the attention of investors looking to capitalize on the growing demand for high-quality veterinary care. This analysis will compare the financial performance and potential investment opportunities of IDEXX Laboratories and Zoetis stocks.

IDEXX Laboratories or Zoetis?

When comparing IDEXX Laboratories and Zoetis, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between IDEXX Laboratories and Zoetis.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. IDEXX Laboratories has a dividend yield of -%, while Zoetis has a dividend yield of 1.23%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. IDEXX Laboratories reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%. On the other hand, Zoetis reports a 5-year dividend growth of 24.37% year and a payout ratio of 31.44%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with IDEXX Laboratories P/E ratio at 41.71 and Zoetis's P/E ratio at 32.83. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. IDEXX Laboratories P/B ratio is 22.33 while Zoetis's P/B ratio is 15.24.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, IDEXX Laboratories has seen a 5-year revenue growth of 0.73%, while Zoetis's is 0.54%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with IDEXX Laboratories's ROE at 55.42% and Zoetis's ROE at 47.99%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $434.49 for IDEXX Laboratories and $175.00 for Zoetis. Over the past year, IDEXX Laboratories's prices ranged from $404.74 to $583.39, with a yearly change of 44.14%. Zoetis's prices fluctuated between $144.80 and $201.92, with a yearly change of 39.45%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.